Literature DB >> 20830599

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Masayuki Kurosaki1, Naoya Sakamoto, Manabu Iwasaki, Minoru Sakamoto, Yoshiyuki Suzuki, Naoki Hiramatsu, Fuminaka Sugauchi, Hiroshi Yatsuhashi, Namiki Izumi.   

Abstract

BACKGROUND: This study aimed to develop a model for the pre-treatment prediction of sustained virological response (SVR) to peg-interferon plus ribavirin therapy in chronic hepatitis C.
METHODS: Data from 800 genotype 1b chronic hepatitis C patients with high viral load (>100,000 IU/ml) treated by peg-interferon plus ribavirin at 6 hospitals in Japan were randomly assigned to a model building (n = 506) or an internal validation (n = 294). Data from 524 patients treated at 29 hospitals in Japan were used for an external validation. Factors predictive of SVR were explored using data mining analysis.
RESULTS: Age (<50 years), alpha-fetoprotein (AFP) (<8 ng/mL), platelet count (≥ 120 × 10(9)/l), gamma-glutamyltransferase (GGT) (<40 IU/l), and male gender were used to build the decision tree model, which divided patients into 7 subgroups with variable rates of SVR ranging from 22 to 77%. The reproducibility of the model was confirmed by the internal and external validation (r (2) = 0.92 and 0.93, respectively). When reconstructed into 3 groups, the rate of SVR was 75% for the high probability group, 44% for the intermediate probability group and 23% for the low probability group. Poor adherence to drugs lowered the rate of SVR in the low probability group, but not in the high probability group.
CONCLUSIONS: A decision tree model that includes age, gender, AFP, platelet counts, and GGT is useful for predicting the probability of response to therapy with peg-interferon plus ribavirin and has the potential to support clinical decisions regarding the selection of patients for therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20830599     DOI: 10.1007/s00535-010-0322-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  43 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.

Authors:  M Kurosaki; N Enomoto; T Murakami; I Sakuma; Y Asahina; C Yamamoto; T Ikeda; S Tozuka; N Izumi; F Marumo; C Sato
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  Improved detection of prostate cancer using classification and regression tree analysis.

Authors:  Mark Garzotto; Tomasz M Beer; R Guy Hudson; Laura Peters; Yi-Ching Hsieh; Eduardo Barrera; Thomas Klein; Motomi Mori
Journal:  J Clin Oncol       Date:  2005-03-21       Impact factor: 44.544

4.  Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Authors:  Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

5.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

Review 6.  Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.

Authors:  Samuel S Lee; Peter Ferenci
Journal:  Antivir Ther       Date:  2008

7.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response.

Authors:  G Mazzella; A Salzetta; S Casanova; M C Morelli; N Villanova; R Miniero; S Sottili; V Novelli; A Cipolla; D Festi
Journal:  Dig Dis Sci       Date:  1994-04       Impact factor: 3.199

10.  Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.

Authors:  Takeshi Okanoue; Yoshito Itoh; Hiroaki Hashimoto; Kohichiroh Yasui; Masahito Minami; Tetsuo Takehara; Eiji Tanaka; Morikazu Onji; Joji Toyota; Kazuaki Chayama; Kentaro Yoshioka; Namiki Izumi; Norio Akuta; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2009-06-11       Impact factor: 7.527

View more
  11 in total

1.  Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.

Authors:  Naoki Hiramatsu; Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Fuminaka Sugauchi; Akihiro Tamori; Sei Kakinnuma; Kentaro Matsuura; Namiki Izumi
Journal:  J Gastroenterol       Date:  2011-06-17       Impact factor: 7.527

2.  Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Authors:  Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Ke Ih Kim; Yoshi-hiro Ide; Lin Deng; Ikuo Shoji; Yasuhito Tanaka; Yutaka Hasegawa; Mitsuhiro Ota; Hak Hotta
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

3.  Developing screening services for colorectal cancer on Android smartphones.

Authors:  Hui-Ching Wu; Chiao-Jung Chang; Chun-Che Lin; Ming-Chang Tsai; Che-Chia Chang; Ming-Hseng Tseng
Journal:  Telemed J E Health       Date:  2014-05-21       Impact factor: 3.536

4.  Risk stratification of spontaneous bacterial peritonitis in cirrhosis with ascites based on classification and regression tree analysis.

Authors:  Ke-Qing Shi; Yu-Chen Fan; Li Ying; Xian-Feng Lin; Mei Song; Ling-Fei Li; Xie-Yan Yu; Yong-Ping Chen; Ming-Hua Zheng
Journal:  Mol Biol Rep       Date:  2011-12-29       Impact factor: 2.316

5.  Patterns of Caregiver Factors Predicting Participation in Trauma-Focused Cognitive Behavioral Therapy.

Authors:  Betty S Lai; Ashwini Tiwari; Shannon Self-Brown; Peter Cronholm; Kelly Kinnish
Journal:  J Child Adolesc Trauma       Date:  2017-07-15

6.  MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.

Authors:  Ayumi Asada; Makoto Shioya; Rie Osaki; Takashi Nishimura; Takayuki Takeuchi; Yoshiaki Okumura; Akira Andoh
Journal:  Biomed Rep       Date:  2014-12-17

7.  Algorithm to determine the outcome of patients with acute liver failure: a data-mining analysis using decision trees.

Authors:  Nobuaki Nakayama; Makoto Oketani; Yoshihiro Kawamura; Mie Inao; Sumiko Nagoshi; Kenji Fujiwara; Hirohito Tsubouchi; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2012-03-09       Impact factor: 7.527

Review 8.  Advanced molecular surveillance of hepatitis C virus.

Authors:  Livia Maria Gonçalves Rossi; Alejandro Escobar-Gutierrez; Paula Rahal
Journal:  Viruses       Date:  2015-03-13       Impact factor: 5.048

9.  A model predicting short-term mortality in patients with advanced liver cirrhosis and concomitant infection.

Authors:  Ying Li; Roongruedee Chaiteerakij; Jung Hyun Kwon; Jeong Won Jang; Hae Lim Lee; Stephen Cha; Xi Wei Ding; Charat Thongprayoon; Fu Shuang Ha; Cai Yun Nie; Qian Zhang; Zhen Yang; Nasra H Giama; Lewis R Roberts; Tao Han
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

10.  The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis.

Authors:  Marwa Khairy; Rabab Fouad; Mahassen Mabrouk; Wafaa El-Akel; Abu Bakr Awad; Rabab Salama; Mayada Elnegouly; Olfat Shaker
Journal:  Hepat Mon       Date:  2013-07-17       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.